• 생물정신의학
• /
• 제7권1호
• /
• pp.85-98
• /
• 2000

1) 성기능장애 빈도는 정신분열병 환자군이 80%로 대조군 42%에 비해 유의하게 높았다(p<0.001). 성반응 주기에 따른 장애유형은 성적욕망장애 76%, 발기장애 75%, 발기유지장애 75%, 성적극치감의 질적감소 61%, 지루 50%, 사정시 정액량의 감소 44% 순서로 많았다. 성적극치감 횟수의 감소는 32%로 다른 장애유형에 비해 적었으며, 조루를 호소하는 경우도 15%나 되었다. 2) PRL 및 5-HT 측정치는 환자군에서 $28.5{\pm}20.6ng/ml$, $298.5{\pm}89.1ng/ml$으로서 대조군 $10{\pm}5.6ng/ml$, $169.2{\pm}37.8ng/ml$보다 유의하게 높았다(p<0.001). TST 측정치는 환자군이 $4.3{\pm}1.5ng/ml$, 대조군이 $4.5{\pm}1.2ng/ml$로 양군 모두 유의한 차이가 없었다. 3) 성기능장애를 증가시키는 변인은 결혼(미혼), 초발연령, 이병기간, 입원기간, 총약물투여기간 그리고 5-HT 측정치이었다. 특히 5-HT 비정상치군이 정상치군보다 성기능장애가 유의하게 높았다. 그러나 연령, 교육연한, 종교, 경제상태, PRL 및 TST 측정치, 항정신병약물용량, 약물역가, benztropine, ACSE, CGI, BPRS, PANSS, PANSS-CF, MMSE-K 점수와 성기능장애와는 무관하였다. 성기능장애는 정신분열병군에서 높았고, 성기능장애 유형별로는 성적욕망장애와 발기장애가 많았다. 미혼이거나, 초발연령이 높을수록, 질병에 이환된 기간이 길수록, 5-HT 농도가 높을수록 성기능장애가 증가하였다. 비록 혈중 5-HT 농도가 뇌 5-HT 활성을 어느정도 반영하는지는 알 수 없으나, 정신분열병 환자의 일차 병인인 과도한 5-HT 활성으로 인한 직접적인 성기능 억제효과 때문에 장애가 초래한다고 생각된다.

• 생물정신의학
• /
• 제19권4호
• /
• pp.193-198
• /
• 2012

Objectives Despite the growing research interest in the role of immunological markers in schizophrenia, a few studies, with conflicting results, have focused on the association between high sensitivity C-reactive protein (hs-CRP) levels and clinical characteristics in schizophrenia. The aim of the present study was to examine the association of serum hs-CRP with psychopathology in schizophrenia. Methods Fifty-five inpatients with schizophrenia or schizoaffective disorder were enrolled. Serum levels of hs-CRP were measured, and each patient was assessed with the Korean version of the Positive and Negative Syndrome Scale (PANSS). Results In correlation analysis of hs-CRP with PANSS subscales, positive subscale score has significant positive correlation (r = 0.271, p = 0.046). In independent t-test analysis, subjects with hs-CRP > 0.3 mg/dL (elevated CRP group, n = 43) had significantly higher PANSS positive subscale score (t = -3.273, df = 24.107, p = 0.003) than those with hs-CRP ${\leq}$ 0.3 mg/dL (normal CRP group, n = 12). Conclusions Elevated serum levels of high sensitivity C-reactive protein in schizophrenia are associated with the severity of psychotic symptoms.

• 생물정신의학
• /
• 제8권1호
• /
• pp.106-110
• /
• 2001

Background : Dopamine receptors have been regarded as a strong candidate involved in etiology of schizophrenia and a target for various antipsychotic drugs. The purpose of our study was to investigate whether dopamine $D_1$ receptor(DRD1) gene polymorphisms would predict the treatment response to antipsychotics in schizophrenia. Method : One hundred thirty-four schizophrenic patients, who met DSM-IV criteria for schizophrenia were entered into a 48 -week study. The psychopathology of the patients was assessed at baseline, 12th, 24th 48th weeks of treatment by PANSS. Responders were defined by a 20% of the reduction in total PANSS score at end point. The genomic DNA fragment corresponding to nucleotides of dopamine $D_1$ receptor gene was amplified by polymerase chain reaction(PCR). Result: Neither allelic frequencies nor genotypes for dopamine $D_1$ receptor differed significantly between responders and non-responders. Also, there was no difference of changes of PANSS scores among three genotype groups of the dopamine $D_1$ receptor. Conclusion : Allelic variation in the dopamine $D_1$ gene is not associated with individual differences in antipsychotic response.

• 생물정신의학
• /
• 제4권1호
• /
• pp.121-126
• /
• 1997

본 연구는 정신분열증 환자 38명을 대상으로 하여 haloperidol과 fluoxetine을 8주간 병합투여 하였고, PANSS, CGI, Simpson-Angus 척도를 투여전과 투여후 2, 4, 6, 8주에 시행하여 임상증상 및 추체외로 부작용을 평가하였다. 결과는 다음과 같다. 1) 8주간의 연구기간동안 양성, 음성증상의 유의한 변화가 없었다. 2) 8주의 연구기간동안 추체외로 부작용의 증가가 나타나지 않았다. 이는 기존 연구에서 fluoxetine에 의해 haloperidol의 혈중농도가 증가하여 효과 및 부작용이 증가한다는 연구보고와는 다르며, 이 결과는 haloperidol과 fluoxetine의 병합사용을 안전하게 할 수 있다는 것을 의미한다고 하겠다.

• 생물정신의학
• /
• 제20권3호
• /
• pp.91-96
• /
• 2013

Objectives The aim of this study is to evaluate the association between rs6280 and rs905568 genetic polymorphism of DRD3 gene and the treatment response of amisulpride. Methods After six weeks treatment of amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S). The genotyping for rs6280 and rs905568 was performed using TaqMan single nucleotide polymorphism (SNP) genotyping assay. Results There was no significant difference in the frequency of genotype and allele of rs6280 between the responders and non-responders based on the total, positive, and general score of PANSS and CGI-S score. However, there was a significant association between this SNP and treatment response in the negative score of PANSS (${\chi}^2=5.23$, p = 0.022). There was no significant association between rs905568 and the response in positive, negative, general, and total PANSS score and CGI-S score. Conclusions This is the first positive association study between DRD3 gene and the treatment response of negative symptoms to amisulpride in Korean schizophrenia patients. A larger scale research on more SNP of the DRD3 gene will make a progress in the study of pharmacogenetics on the treatment response of the amisulpride.

• 정신신체의학
• /
• 제29권2호
• /
• pp.207-212
• /
• 2021

항-N-methyl-D-aspartate 수용체 뇌염(Anti-NMDAR encephalitis)은 NMDA 수용체에 대한 자가항체로 매개되는 신경 염증성 질환으로 초기에 뚜렷한 신경학 증상 없이 망상, 지각이상, 와해된 행동, 심한 불안, 인지기능저하 등의 정신증상이 두드러질 수 있다. 면역치료 혹은 종양제거와 같은 조기치료가 좋은 예후 인자이므로 질병초기에 정신질환과 구분하여 항-NMDAR 뇌염을 진단하는 것이 중요하다. 본 증례에서는 간질과 정신병적 증상을 보이는 26세 여성 A씨를 조기에 항-NMDAR 뇌염으로 확진한 뒤 양성 및 음성증상 척도(Positive and Negative Syndrome Scale, PANSS)를 사용하여 평가하였다. A씨의 항-NMDAR 뇌염 초기의 정신증상으로 PANSS에서 양성하위척도 보다 음성하위척도 점수가 더 높았다. 정신장애와 비교하여 항-NMDAR 뇌염 초기에 음성증상과 인지장애가 더욱 두드러질 가능성이 있다. A씨의 치료로는 rituximab과 난소 기형종의 제거가 효과적이었고 항정신병제로는 quetiapine을 사용하였다. 특히 젊은 여성에서 망상, 행동장애와 함께 음성증상, 인지장애, 긴장증, 의식수준의 변화, 운동이상증상 등이 관찰될 때 항-NMDAR 뇌염에 대한 평가를 고려해야 한다.

• 생물정신의학
• /
• 제4권1호
• /
• pp.127-131
• /
• 1997

Objective : To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study. Method : Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen. Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points ; baseline, 2, 4, 6, and 8 weeks of treatment. Results : The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI, and S-A scale scores at any between sertaline and placebo treatment. Conclusion : This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.

• 동의신경정신과학회지
• /
• 제27권3호
• /
• pp.147-155
• /
• 2016

Objectives: Schizophrenia is a serious disease that influences not only the patients themselves but also their family and the society. In this case, we employed art therapy and Korean traditional medicine for treating a schizophrenia patient.Methods: The patient was diagnosed with schizophrenia, and the main complaints were hallucination, visual hallucination and catatonic behavior. We treated the patient with art therapy and Korean traditional medicine including acupuncture, moxa and herbal medicine. We used the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) for assessment.Results: After treatment, clinical symptoms were improved and the BPRS and PANSS scores were decreased, especially the scores for anxiety, depression and poor rapport.Conclusions: Combined treatment with art therapy and Korean traditional medicine can be effective for treating chronic schizophrenia.

• 한국자기공명학회논문지
• /
• 제5권1호
• /
• pp.56-65
• /
• 2001

Localized in vivo proton magnetic resonance spectroscopy (MRS) was performed to evaluate metabolic alterations in the right and left frontal lobe before and after neuroleptic treatment of schizophrenic patients (n=24) and a group of healthy normal subjects (n=20). Proton metabolic ratios obtained from the 8㎤ yokels in the right and left frontal lobe were compared with the clinical assessment of PANSS for each subject. There was no significant difference in the metabolic ratios between the right and the left frontal lobes in either the schizophrenic group or the control group, indicating no laterality. Compared with those of the normal control group, NAA/Cr and (GABA+Glu)/Cr ratios of the schizophrenic patients showed significantly lower (p=0.023) and higher (p=0.005) value, respectively. The (GABA+Glu)/Cr ratio of the schizophrenic patients was generally decreased after neuroleptic treatment, while the NAA/Cr ratio was not changed. Significant correlation between the (GABA+Glu)/Cr ratio and the clinical symptom scores assessed by PANSS was established. The present study supports the “hypofrontality” hypothesis of schizophrenia on the basis of the altered metabolic ratios before and after neuroleptic treatment.

• 대한한방내과학회지
• /
• 제27권2호
• /
• pp.546-553
• /
• 2006

Schizophrenia is a disturbance condition that lasts for at least 6 months and includes at least 1 month of active-phase symptoms(i.e., two [or more] of the following : delusions, hallucinations. disorganized speech, grossly disorganized or catatonic behavior, negative symptoms) In this study, we report one case of schizophrenia with acute cerebral infarction. The patient has been diagnosed with schizophrenia more than 20 years ago, and after this recent cerebral infarction, all of her schizophrenic symptoms such as auditory hallucination, delirium, depression, insomnia were aggravated. Her schizophrenic symptoms, PANSS and NIHSS total scores were considerably reduced after oriental treatment(Guibi-tang(歸脾湯)), so we report this as a potential treatment.